Perindopril arginine

Quick links

Choose a section

Quick links to important sections

Advertisements

Perindopril arginine

Selected form

Advertisements

Overview of Perindopril arginine

Quick Facts

Property Description
Active ingredient Perindopril
Form Oral Tablet
Pharmacological class ACE Inhibitor (Angiotensin-Converting Enzyme Inhibitor)
General purpose Cardiovascular support and circulatory system management
Differentiation Specific salt form chosen for stability

What Type of Medicine Is Perindopril Arginine?

Perindopril arginine is a synthetic medication that is an Angiotensin-Converting Enzyme (ACE) inhibitor. This class of drugs is used to help promote the relaxation and dilation (widening) of blood vessels, thereby reducing the overall resistance to blood flow in the circulatory system.

This approach to reducing vascular resistance is a cornerstone of modern heart care. ACE inhibitors, like perindopril, are foundational agents in managing conditions where easing the strain on blood vessels is critical for heart health. This means the medicine helps your heart work more easily by gently encouraging blood vessels to relax.

What Is the Difference Between Perindopril and Perindopril Arginine?

Perindopril arginine is a specific salt form of the active pharmaceutical ingredient (API), which is Perindopril. The core drug, Perindopril, is chemically bonded with the amino acid arginine to create a stable, oral compound.

This arginine salt formulation is used as a differentiating factor because it is known for its chemical stability and specific absorption characteristics. The choice of salt form is essential for the physical and chemical properties of the final medicine. In simple terms, the arginine ensures a more consistent and reliable dose of the active medicine is delivered.

What Is Perindopril Arginine Used for Generally?

The general therapeutic purpose of Perindopril arginine is to support and manage chronic conditions affecting the heart and the circulatory system. Its core action of relaxing the blood vessels makes it valuable for establishing a healthy, sustainable baseline for circulatory function.

By consistently maintaining wider blood vessels, the medication effectively helps decrease the workload on the heart, providing a protective and supportive benefit to the entire vascular network.

Regulatory References

  1. Coversyl - referral
Advertisements

What side effects are possible with Perindopril arginine?

Possible side effects and safety information

The safety profile of Perindopril arginine, an Angiotensin-Converting Enzyme (ACE) inhibitor, is officially classified based on the frequency and the physiological systems affected.

Adverse reactions are formally grouped by regulatory authorities into System-Organ Classes (SOCs) and frequency bands.

Classification Common Adverse Reactions (1–10%)
Respiratory Persistent, nonproductive cough
Nervous System Headache, dizziness, vertigo, taste disturbance
Vascular Symptomatic hypotension (low blood pressure)
Gastrointestinal Nausea, vomiting, abdominal pain, diarrhea, constipation

Serious adverse reactions are rare but documented in regulatory labeling. The most significant serious risk is Angioedema, a rapid swelling of the face, limbs, lips, tongue, glottis, and/or larynx, which can occur at any point during treatment. Acute Renal Failure is also noted as a very rare but serious reaction.

The official labeling includes specific safety considerations for patient groups. Use is formally contraindicated during the second and third trimesters of pregnancy due to the risk of fetal and neonatal injury. Older adults and patients with renal impairment require particular caution due to altered elimination of the drug’s active metabolite. Furthermore, symptomatic hypotension is most frequently observed at the initiation of therapy or during dose increases. The labeling also notes a higher documented incidence of Angioedema in Black patients compared to non-Black patients.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for Perindopril arginine defines the overdose profile primarily around the risk of severe cardiovascular events due to excessive blood pressure reduction.


Documented Overdose Presentations

The most frequently documented clinical sign of an overdose is Hypotension (low blood pressure), which can progress to Profound Hypotension and Circulatory Shock. Other recognized manifestations listed in labeling include Bradycardia (slow heart rate), Tachycardia (fast heart rate), Dizziness, and Hyperventilation. Severe outcomes documented in official labeling include Acute Renal Failure and Electrolyte Disturbances.

Required Emergency Actions

The regulatory mandate is to seek immediate medical attention upon the suspicion of overdose. Emergency medical services must be contacted immediately if symptoms involve signs of profound hypotension or circulatory shock. Hospital monitoring is required for the continuous observation of vital signs and laboratory functions.

Supportive Management

No specific antidote is known for Perindopril arginine overdose. Management is officially described as symptomatic and supportive treatment, including the intravenous infusion of normal saline for hypotension. For cases of recent ingestion, procedures such as Gastric Lavage and the administration of Activated Charcoal are documented. The active metabolite is dialyzable via hemodialysis.

Advertisements

Therapeutic Uses of Perindopril arginine

Main Uses and Therapeutic Areas

Perindopril arginine is a form of medicine belonging to the angiotensin-converting enzyme (ACE) inhibitor class. Its primary therapeutic domains are focused on managing conditions associated with acute or disruptive episodes, such as Hypertension (High Blood Pressure), Congestive Heart Failure, and Stable Coronary Artery Disease.

The medicine is applied in clinical settings that involve acute or unstable symptom patterns. The medication is used to address symptoms related to heightened physiological activity across these condition categories. For example, the medication assists with maintaining functional stability and is commonly used to help with maintaining a more stable blood pressure. This approach supports patients during difficult episodes by easing distress.

The overall benefit provided to the patient is supportive. This treatment provides support that helps ease the overall symptom burden and contributes to improved comfort during symptomatic periods. It is applied in addressing symptoms linked to organ-specific functional stress and systemic imbalance, assisting patients with coping more steadily with symptom fluctuations.


Quick Fact: Relief for Symptoms that interfere with daily functioning


Regulatory References

  1. NPS MedicineWise (Australia's independent medication authority)
Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Perindopril Arginine?

Eligibility for Perindopril arginine is strictly defined by regulatory documents, focusing on patient history, life stage, and physiological conditions. The medicine is primarily approved for adult patients (aged 18 and over).


Absolute Contraindications

Perindopril arginine must not be used in patients with a history of angioedema (associated with previous ACE inhibitor therapy, hereditary, or idiopathic) or known hypersensitivity to the drug or any other ACE inhibitor.

Use is contraindicated during the second and third trimesters of pregnancy and is not recommended in the first trimester or for breastfeeding women. It is also prohibited for patients receiving sacubitril/valsartan and for patients with diabetes mellitus or renal impairment (GFR < 60 mL/min/1.73 m^2) who are concurrently using aliskiren.


Population and Condition Restrictions

  • Pediatric Use: Safety and efficacy have not been established in children and adolescents under 18 years of age, and use is not recommended.
  • Renal Function: The medicine is contraindicated in patients with severe renal impairment (CrCl < 30 mL/min). Use in older adults and those with moderate renal impairment is conditional and requires medical assessment of kidney function.
Advertisements

What should I know about interactions with other medicines?

Officially documented interactions with Perindopril arginine involve various pharmacodynamic and administrative restrictions defined in regulatory labels. The combination with Sacubitril/Valsartan is contraindicated, requiring a mandatory 36-hour wash-out period before starting or stopping either medication due to the significantly increased risk of angioedema. Similarly, co-administration with Aliskiren is contraindicated specifically for patients with diabetes or impaired renal function. The use of certain extracorporeal treatments, such as haemodialysis with polyacrylonitrile high-flux membranes, is also prohibited due to the risk of severe reactions.

A major interaction domain involves substances that increase the risk of hyperkalaemia (elevated serum potassium levels). This additive effect is formally documented with potassium-sparing diuretics (e.g., Spironolactone), potassium supplements, and potassium-containing salt substitutes.

Other clinically significant interactions include Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which may attenuate the antihypertensive effect and increase the risk of renal function deterioration. Co-administration with Lithium is officially documented to reduce its renal clearance, which increases serum lithium concentrations and the risk of toxicity. Finally, the regulatory review confirms that the co-administration of the arginine salt formulation with food results in no clinically relevant alteration to the exposure of the active metabolite, perindoprilat.

Advertisements

Mechanism of Action

Perindopril arginine is an orally administered prodrug that is hydrolyzed in vivo to its active metabolite, perindoprilat. Perindoprilat acts as a competitive inhibitor of the enzyme angiotensin-converting enzyme (ACE), also known as peptidyl-dipeptidase A or kininase II. ACE is a crucial component of the renin-angiotensin-aldosterone system (RAAS), primarily found in the endothelium of the pulmonary and renal vasculature.

By binding to the active site of ACE, perindoprilat prevents the conversion of the inactive decapeptide angiotensin I to the active octapeptide angiotensin II. The resulting molecular cascade leads to a dose-dependent reduction in circulating and tissue concentrations of angiotensin II. Angiotensin II normally acts via the AT1 receptor to promote vasoconstriction, aldosterone release from the adrenal cortex, and increased sympathetic outflow. The reduction in angiotensin II diminishes these downstream effects. Additionally, ACE is responsible for the deactivation of the vasodilator bradykinin; its inhibition by perindoprilat leads to an accumulation of bradykinin, which promotes nitric oxide- and prostacyclin-mediated vasodilation. The system-level physiological consequence is a reduction in total peripheral vascular resistance and a diminished sodium and water reabsorption in the distal nephron.

Advertisements

Dosage and Administration Information

How to Use Perindopril arginine

Perindopril arginine is an oral tablet prescribed for chronic cardiovascular management and is consistently administered once daily. The administration protocol is standardized across approved indications and is defined by the official starting dose, timing relative to meals, and specific titration schedules.

Official Dosing and Administration

The tablet must be taken in the morning and preferably before a meal to ensure proper absorption. Dosing follows a structured titration period, meaning the starting dose must be maintained for a set time before any increase is considered. For stable coronary artery disease, for example, the dose is initiated at 5 mg once daily for two weeks before potentially increasing to the maximum maintenance dose.

Indication Initial Dose Maximum Daily Dose
Hypertension 5 mg once daily 10 mg once daily
Stable Coronary Artery Disease 5 mg once daily for 2 weeks 10 mg once daily
Symptomatic Heart Failure 2.5 mg once daily 5 mg once daily

Population and Procedural Rules

Certain patient populations require a lower starting numerical strength. For older adults, the initial dose is typically 2.5 mg once daily, with subsequent increases depending on the individual's kidney function. Use in children and adolescents is not recommended. Furthermore, if a patient is starting therapy while also using a diuretic, the lowest starting dose of 2.5 mg is typically employed, often following a temporary discontinuation of the diuretic. If a daily dose is forgotten, the official guidance is to not take a double dose to compensate.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Perindopril Arginine


Evidence for Use in Managing High Blood Pressure (Hypertension)

Randomized Controlled Trials (RCTs) have primarily been applied to research involving Perindopril (the active component) and individuals with high blood pressure (hypertension). These trials were designed to observe changes in key measurements like Systolic and Diastolic Blood Pressure (SBP/DBP), and to monitor the incidence of major cardiovascular events, such as stroke or heart attack, over defined time intervals. These studies were applied in research contexts involving fluctuating or unstable symptoms in adults across varying degrees of hypertension.

Studies monitored blood pressure levels and studies report patterns related to generally different SBP and DBP in the study group compared to the placebo groups during the monitoring period. Long-term studies, some extending four years or more, were observed in research exploring short-term symptom changes and examined whether these patterns extended to outcomes monitoring physiological strain or stress by describing patterns observed in the incidence of cardiovascular events.

Research describes that findings related to blood pressure patterns were reported as consistent across the large-scale RCTs conducted. However, a key limitation noted in research is the difficulty in entirely separating the documented blood pressure changes from potential additional effects the medicine was studied for. Comparative evidence is lacking for many of the newest available blood pressure treatments, as research primarily examined older alternatives or placebo.


Evidence for Use in Symptomatic Heart Failure

The evidence base for symptomatic heart failure relies on Placebo-controlled RCTs and large Meta-analyses. These studies examined changes in functional capacity, such as exercise tolerance, and outcomes related to systemic or functional imbalance, like the frequency of hospitalization due to heart failure. The research was conducted on adults with mild to moderate symptoms, often using the drug alongside other established therapies.

Trials reported patterns in the changes measured in functional measures, such as exercise tolerance, for the studied population compared to placebo. Reported data described rates of hospitalization related to heart failure and mortality endpoints in specific long-term trial populations. These findings describe patterns observed during follow-up periods ranging up to 30 months.

What remains uncertain is the research base for people with the most severe stage of heart failure (NYHA Class IV), as data for this group remain insufficient, and the drug was not typically evaluated in this setting. Additionally, follow-up durations were limited, meaning that long-term patterns related to the durability of findings beyond two to three years are not fully established.


Evidence for Use in Stable Coronary Artery Disease

The evidence for stable coronary artery disease (CAD) comes primarily from large-scale, long-term RCTs, such as the EUROPA study. These studies were applied in research contexts involving fluctuating or unstable symptoms in adults with established stable CAD, including those who had experienced a previous heart attack or revascularization procedure. Research examined a composite outcome that included cardiovascular death, non-fatal myocardial infarction, and cardiac arrest over long observation periods, typically four years or more.

The findings describe patterns observed in the rate of the major cardiovascular events composite endpoint in the study group compared to the placebo group. These outcomes monitoring physiological strain or stress were observed over the defined time intervals. However, studies exploring the change in individual secondary outcomes, such as total mortality, findings were mixed and did not always describe statistically different patterns across all trials.

A research limitation is that separating the cardiovascular findings from the concomitant blood pressure-lowering patterns is complex. Furthermore, the results apply only to the populations studied, meaning there is limited information available for people with unstable or newly emerging CAD symptoms.


Evidence for Use in Preventing Recurrent Stroke

The research examining the prevention of recurrent stroke utilized large-scale RCTs on adults who had a history of stroke or a transient ischaemic attack (TIA). Studies explored outcomes capturing phases of heightened symptom activity, primarily focusing on the incidence of total, fatal, and non-fatal stroke (both ischemic and hemorrhagic types) over a long duration of observation. Research commonly examined the drug's use in combination with a diuretic.

Studies reported how symptoms evolved in the observed populations, and findings describe patterns in the risk profile for the recurrence of total stroke events. This pattern was observed in some studies, particularly when the drug was used with the concurrent use of a diuretic. The evidence contributes to the broader evidence landscape related to the ACE inhibitor drug class.

Certainty remains low regarding the isolated effect of Perindopril without the diuretic, as the patterns observed appear to be most pronounced when combination therapy is utilized. Furthermore, the evidence level is considered modest because the primary findings often rely on the collective patterns observed across the ACE inhibitor drug class.


Long-Term Studies and Follow-Up

Research for this medication includes trials with long-term follow-up durations, particularly for chronic conditions like hypertension and stable coronary artery disease, where observation periods of four years or more was observed in some studies. This extended observation allows researchers to collect data related to outcomes reflecting daily functioning or activity level and major cardiovascular events over defined time intervals.

For indications like stable CAD and hypertension, the long-term studies provide context but not individual predictions about the potential for changes in major outcomes. However, the data for heart failure and for some special populations, long-term effects are not fully established, as follow-up durations were limited in specific studies. Research highlights what is known—and what is still uncertain—regarding the durability of the observed patterns over many years of continued use.


Evidence in Specific Patient Groups

The research has studied for the use of this medicine across different patient groups. Older adults with hypertension or heart failure have been specifically included and monitored in various trials, meaning data related to this group remain available. Similarly, research examined populations with various concurrent conditions (comorbidities).

However, certain aspects remain uncertain. Limited data are available for groups such as children and adolescents with heart conditions. Furthermore, evidence quality varies across studies when examining outcomes for highly specific, narrowly defined subgroups, and findings describe group patterns, not personal outcomes.


What is Still Uncertain About the Research for Perindopril Arginine

Despite the large-scale RCTs, certain knowledge gaps and limitations persist within the evidence landscape. For instance, comparative evidence is lacking for many of the newest treatments now available for hypertension and heart failure. Individual secondary endpoints presented findings that were mixed in the large-scale clinical studies.

Data for certain groups remain insufficient, especially for patients with the most severe forms of heart failure (NYHA Class IV). Additionally, while the long-term studies monitored cardiovascular outcomes, long-term effects are not fully established beyond the observation period of the largest trials. Research is ongoing to further contextualize the evidence and fill these gaps.

Key Studies & References

  1. Public Assessment Report for Perindopril arginine Mylan (Hypertension, Heart failure, Stable coronary artery disease)
  2. Label: PERINDOPRIL ERBUMINE tablet (FDA/NIH DailyMed)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Perindopril arginine (FAQ)

Q: What is perindopril arginine and what is it used for?

Perindopril arginine is a medicine that belongs to a group of drugs called angiotensin-converting enzyme (ACE) inhibitors. It is used to treat high blood pressure (hypertension), heart failure, and to reduce the risk of cardiac events like heart attack in patients with stable coronary artery disease.

Q: How should I take perindopril arginine?

Perindopril arginine is typically taken once a day by mouth. It can be taken with or without food. Follow your doctor's instructions exactly regarding the dose and timing. It is important to try to take your medicine at the same time each day.

Q: What should I do if I miss a dose?

If you miss a dose, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not double your dose to make up for a missed one.

Q: What are common side effects of perindopril arginine?

Common side effects may include dizziness, especially when standing up, headache, fatigue, and a dry, persistent cough. If the cough becomes bothersome, inform your doctor. Most side effects are mild and temporary.

Q: Can I take perindopril arginine if I am pregnant or breastfeeding?

No, perindopril arginine should not be used during pregnancy, especially during the second and third trimesters, as it can harm the fetus. If you become pregnant while taking this medicine, stop taking it and contact your doctor immediately. It is also generally not recommended while breastfeeding.

Q: What types of medicines should I avoid while taking perindopril arginine?

You should avoid taking certain medications without talking to your doctor first, including:

  • Potassium-sparing diuretics or potassium supplements, as these can increase potassium levels.
  • Nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, which may reduce the effect of perindopril and increase the risk of kidney problems.
  • Lithium, as perindopril can increase the levels of lithium in the blood.
  • Other blood pressure-lowering drugs, as this could lead to dangerously low blood pressure.
Advertisements

How should Perindopril arginine be stored and disposed of?

Storage and Disposal of Perindopril Arginine

Official regulatory documents define specific requirements for storing and disposing of Perindopril arginine to maintain drug quality and ensure public safety.


Official Storage Requirements

Condition Requirement
Temperature Store at room temperature, away from excess heat.
Protection Keep the container tightly closed to protect the contents from moisture.
Container Keep the medicine in its original container, which often includes a desiccant.
Child Safety Store the medication out of the reach and sight of children.

Some official labels specify that if the container is a bottle, the contents should be used within six months after first opening.


Official Disposal Instructions

Do not dispose of this medication via wastewater or household garbage. Unused or expired medication must be returned to a pharmacy or an authorized drug take-back program. These measures are required to prevent environmental contamination and protect water sources.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Perindopril arginine found in:

A-Z Index: